Fig. 5

NOX1 inhibition dampens the upregulation of pro-inflammatory markers during HCC development. After 25 weeks of DEN administration and 15 weeks of vehicle/GKT771 treatment, HCC lesions and non-tumoral surrounding liver tissue were sampled for mRNA expression analysis. The expression of inflammatory markers (IL6, TNFα, IL1β, CCR2, CCL2, Caspase 1 and NLRP3) and of the immune suppressive marker PDL1 was performed via RT-qPCR. Data shown as mean ± SEM. ^nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently